Hims & Hers Health (HIMS) is back in the spotlight after Hers Hair launched in the UK, extending its clinician-led hair loss program and online care model to British women.
These international launches arrive after a stretch of mixed trading for Hims & Hers Health, with the share price down 15.74% year to date and the 1-year total shareholder return falling 45.19%. Over a 3-year period, however, the total shareholder return is still more than 3.5x.
Scan Hims & Hers Health alongside other fast-scaling digital care players by checking out the hand picked 33 healthcare AI stocks that are drawing attention in telehealth and data driven medicine.
Bulls see Hims & Hers Health using UK and Australian launches to build on rapid multi year returns. Bears focus on recent share price declines and ongoing losses. Which story does the current valuation echo?
Most Popular Narrative: 84% Undervalued
On the most followed narrative, Hims & Hers Health screens as heavily discounted, with a fair value of $171.19 against a last close of $28.15. This puts the attention squarely on its long term expansion plan.
The thesis is not about one medication, one category or one quarter. It is about a company repeatedly following the same playbook while expanding its addressable market. More customers. More categories. More countries. More services per customer. Higher ARPU. Better operating leverage. That is the Multi-Dimensional Growth Engine. The combination of execution, expanding opportunity and improving economics suggests that the disconnect between Hims'' underlying growth potential and current market pricing remains substantial, both in the short and long term.
See why 82 investors see Hims & Hers Health as 84% undervalued.
Result: Fair Value of $171.19 (UNDERVALUED)
Still, the Hims & Hers Health story could be knocked off course by slower uptake in new international markets or continued net losses that pressure its reinvestment capacity.
Find out about the key risks to this Hims & Hers Health narrative.
Another View: Hims & Hers Health Looks Pricey On Sales
The SWS DCF model points to Hims & Hers Health trading well below an estimated fair value of $70.71, but the picture changes when you look at simple sales multiples. The stock trades on a P/S of 2.5x, which is higher than the US Healthcare sector at 1.3x and above peers at 2.2x.
Our fair ratio for Hims & Hers Health sits at 4.6x P/S, almost double the current level. This suggests the market could either move closer to that figure over time or keep treating the stock as expensive relative to its group. Which story do you think investors will lean into next.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed opinions are clear, and that is exactly why Hims & Hers Health is interesting right now. Act quickly: review the underlying numbers and broader context, then pressure test your own thesis against the 2 key rewards and 1 important warning sign.
Looking For More Investment Ideas Beyond Hims & Hers Health?
If Hims & Hers Health has you thinking harder about pricing and potential, broaden your watchlist with a few focused stock shortlists that sharpen your next move.
- Target resilience first and stress test your downside by scanning 32 resilient stocks with low risk scores that aim to keep volatility in check when markets get choppy.
- Hunt for quality at a discount and see which opportunities pop up on the 20 high quality undiscovered gems before wider attention pushes valuations higher.
- Build a sturdier core in your portfolio and filter for balance sheet strength using the list of solid balance sheet and fundamentals (25 results) while quality still looks attractively priced.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com